Sanofi CFO Says 2017 the Toughest Year on Diabetes

The transcript discusses the challenges faced by a company in the diabetes sector, including declining sales due to biosimilar competition and pricing pressures. Despite these challenges, other divisions such as specialty care and vaccines have shown robust growth, contributing to an overall positive performance. The company provides guidance for future expectations, indicating that the current year may be the toughest due to increased competition. Additionally, the company is investing in new drug launches, particularly a breakthrough treatment for dermatitis, which shows promising potential.

What positive developments were noted in other divisions outside of diabetes?

What new drug is mentioned as a breakthrough for treating dermatitis?